Clinical Trials Patients Programs 
NORML
MAY 26, 2020
The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain. Additional information regarding cannabinoids and pain appears online h ere.
NORML
APRIL 30, 2020
.” The CDC’s interest in alternative methods of chronic pain management may be of particular significance to many medical cannabis patients. According to state-registry records, “Chronic pain is currently and historically the most common qualifying condition reported by medical cannabis patients (67.5
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JULY 21, 2021
The study is expected to be the world’s first Phase 2a clinical trial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia. The open-label Phase 2a clinical trial will evaluate the efficacy of TRYP-8802, an oral formulation of synthetic psilocybin, in tandem with psychotherapy for treating fibromyalgia.
Project CBD
OCTOBER 26, 2023
With a few exceptions, tumor cells throughout the body have cannabinoid receptors on their surface, and THC can bind to these receptors and induce apoptosis or programmed cell death. I advise my patients to stop using cannabis for 36 to 48 hours prior to chemotherapy and to start again 36 to 48 hours after their session.
Veriheal
MAY 26, 2022
Patients around the world are in need of natural, alternative medical solutions, and Realm of Caring (RoC) is on a mission to serve them. RoC also works to increase patients’ access to medical cannabis by helping U.S. To date, Veriheal’s global team has helped hundreds of thousands of patients gain access to medical cannabis. “The
Otherside Farms
JANUARY 25, 2019
A medical marijuana patient in Los Angeles with inoperable liver cancer has been removed from Cedars-Sinai Medical Center’s transplant list after testing positive for marijuana. Sixty-three-year-old medical marijuana patient Norman B. The letter also urges Cedars-Sinai to change its transplant eligibility policy. Dr. Steven D.
Cannabis Law Report
OCTOBER 26, 2021
The agreement between the two companies will see Procaps making IHL-42X for Incannex’s Phase 2, Phase 3, and open-label clinical trials. If these trials are successful and IHL-42X is approved for the market, Procaps will also make IHL-42X for patients.
Expert insights. Personalized for you.
277 
Let's personalize your content